ClinicalTrials.gg
Enrolling by invitationNCT07323901GRAPE-GDMUpdated Jan 7, 2026

GRAPE-GDM Prospective Comperative Trial - Grape Juice as a Replacement Drink for Gestational Diabetes Screening

An interventional study of Participants will consume 500 ml of commercially available grape juice which contains 50g of sugar, serving as an alternative glucose load. in Pregnancy - Prenatal Testing, sponsored by Bnai Zion Medical Center. Enrolling by invitation at 1 site in Israel. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-07.

Sponsored by Bnai Zion Medical Center · Not applicable, Interventional, and Screening

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Study summary

Study Type: Observational, prospective, multicenter comparative study

Primary Purpose: The goal of this study is to evaluate whether grape juice can serve as an effective alternative to the standard 50g glucola drink for gestational diabetes screening in pregnant individuals at 24-28 weeks of gestation.

Main Questions:

Can an alternative glucose-loading drink (grape juice) provide comparable blood glucose measurements to the standard GCT? Does grape juice improve patient satisfaction and compliance with gestational diabetes screening?

Comparison Group:

Researchers will compare the standard GCT (50g glucola drink) with the alternative GCT (500 ml grape juice containing 50g sugar). Each participant will undergo both tests, serving as her own control, to assess differences in glucose measurements and patient preferences.

Participant Tasks:

Participants will:

- Undergo two glucose challenge tests (GCT): Standard GCT (50g glucola) at their health maintenance organization (HMO) or hospital.

Alternative GCT (500 ml grape juice) during a scheduled visit or hospitalization.

  • Have blood drawn one hour after each test for glucose measurement.
  • Complete a questionnaire assessing satisfaction and preference between the two methods.
  • Provide follow-up information if they require additional testing (e.g., 100g OGTT).
Read the detailed description

Study Type: Prospective, observational, multicenter comparative study Primary Purpose: To evaluate whether grape juice can serve as an effective alternative to the standard 50g glucola drink for gestational diabetes screening, with the goal of improving patient compliance and satisfaction.

Participant Population: Pregnant individuals at 24-28 weeks of gestation, undergoing routine glucose challenge testing (GCT). Participants will be recruited from Maternal-Fetal Medicine (MFM) clinics, prenatal maternal wards, and social media outreach.

Main Research Questions:

Can an alternative glucose-loading drink (grape juice) provide comparable blood glucose measurements to the standard GCT? Does grape juice improve patient satisfaction and compliance with gestational diabetes screening?

Study Design \& Methods:

Participants: Each participant will undergo both the standard GCT and an alternative GCT using 500 ml of grape juice (containing 50g of sugar).

Control Group: Each participant serves as her own control by completing both tests in a randomized order.

Blood Glucose Measurement: A blood sample will be drawn one hour after ingestion of each drink to compare glucose levels.

Follow-up: If necessary, follow-up phone calls will be conducted to collect results from the standard GCT performed at external clinics.

Outcome Measures:

Primary Outcomes:

Mean difference in blood glucose levels between the standard and alternative GCT.

Proportion of patients with a positive screening result (≥140 mg/dL) for both methods.

Sensitivity, specificity, and predictive values of the alternative GCT compared to the standard test.

Agreement between the two methods using Bland-Altman analysis.

Secondary Outcomes:

Patient satisfaction with both screening methods (measured via a Likert scale). Participant preference between grape juice and glucola. Incidence of adverse events (e.g., nausea, dizziness).

Statistical Analysis:

Pearson's correlation and paired t-tests will assess the agreement between glucose measurements.

ROC analysis will determine the diagnostic performance of the alternative test. Bland-Altman plots will evaluate bias and agreement between the two methods.

Sample Size Calculation:

A minimum of 120 participants is required to detect a clinically significant difference, accounting for attrition.

Recruitment Strategy:

Multicenter Approach: Enrollment from two major hospitals (Bnai Zion and Poria).

Social Media Outreach: Targeted campaigns will inform and recruit participants. Incentives: Participants will receive a complimentary MFM consultation and fetal ultrasound.

Significance:

If grape juice proves to be a viable alternative to the standard GCT, it could improve patient compliance, enhance screening participation, and minimize the discomfort associated with traditional glucose testing.

02

Conditions studied

  • Pregnancy - Prenatal Testing
03

In context

Lead sponsor

Bnai Zion Medical Center is the lead sponsor of 104 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Inclusion Criteria:

Pregnant individuals scheduled for routine GCT at 24-28 weeks. Well-dated pregnancy (confirmed first-trimester ultrasound). Willingness to comply with study protocol.

Exclusion Criteria:

High-risk individuals requiring direct 100g OGTT (e.g., prior GDM, >40, PCOS).

Intolerance to the alternative drink. Gastrointestinal conditions affecting glucose absorption such as active bowel disiease.

Recent administration for fetal lung maturity after standard GCT.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    grape juice

    Participants: Each participant will undergo both the standard GCT and an alternative GCT using 500 ml of grape juice (containing 50g of sugar). Control Group: Each participant serves as her own control by completing both tests in a randomized order.

    Other: Participants will consume 500 ml of commercially available grape juice which contains 50g of sugar, serving as an alternative glucose load.

Interventions

  • OtherParticipants will consume 500 ml of commercially available grape juice which contains 50g of sugar, serving as an alternative glucose load.

    This study investigates a non-carbonated, natural beverage (grape juice) as an alternative glucose-loading method for gestational diabetes screening. Unlike other studies that have explored alternative carbohydrate sources such as jelly beans or gummy candies-which require chewing and may impact dental health-our study focuses on a readily available liquid alternative that closely mimics the glucose absorption kinetics of the standard 50g glucola drink.

06

What researchers measure

Primary outcomes

  1. Blood glucose concentration after test beverage

    Venous plasma glucose ( measured at 60 minutes after each beverage

    Time frame: one hour from injestion of the drink

Secondary outcomes

  1. Participant satisfaction with glucose drink

    Participant reported satisfaction with the consumed glucose drink, assessed using a 5 point Likert scale ranging from 1 (very dissatisfied) to 5 (very satisfied).

    Time frame: One hour after ingestion of the glucose drink.

  2. Participant preference for glucose challenge test drink

    Participant stated preference for the alternative glucose drink compared with the standard glucose challenge test drink, recorded as a categorical variable (alternative drink preferred, standard drink preferred, no preference).

    Time frame: One hour after ingestion of the glucose drink.

  3. Adverse events following glucose drink ingestion

    Occurrence of self reported adverse events following ingestion of the glucose drink, including nausea and dizziness, recorded as present or absent.

    Time frame: One hour after ingestion of the glucose drink.

Other outcomes

  1. Gestational age at birth

    Gestational age at delivery, measured in completed weeks of gestation, based on best obstetric estimate.

    Time frame: At delivery

  2. Neonatal birth weight

    Birth weight of the neonate measured in grams immediately after delivery.

    Time frame: At birth

  3. Mode of delivery

    Mode of delivery categorized as vaginal delivery or cesarean delivery.

    Time frame: At delivery

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — De identified individual participant data collected in this study will not be shared outside the study team.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07323901
Responsible party
Sponsor
First posted
Jan 7, 2026
Start date
Feb 19, 2025
Primary completion
Feb 28, 2027 (estimated)
Completion
Feb 28, 2028 (estimated)
Last update
Jan 7, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion